Reversible, PET-positive, generalized lymphadenopathy and splenomegaly during high-dose interferon-α-2b adjuvant therapy for melanoma

Journal of Immunotherapy

Volumn 31, Issue 7, 2008, Pages 675-678

  Ridolfi, Laura ^a   Cangini, Delia ^b   Galassi, Riccardo ^c   Passardi, Alessandro ^b   Marzullo, Annamaria ^c   Moretti, Andrea ^c   Framarini, Massimo ^d   Tauceri, Francesca ^d   Serra, Luigi ^e   Vanna, Chiarion Sileni ^f   Ridolfi, Ruggero ^a,b  

^a Immunotherapy and Somatic Cell Therapy Unit   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c Department of Nuclear Medicine ^*

^d Departments of Surgery   (Japan)

^e MORGAGNI PIERANTONI HOSPITAL   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Adjuvant high dose interferon 2b; Lymphadenopathy; Melanoma; PET; Splenomegaly

Indexed keywords

ALPHA2B INTERFERON; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CORTISONE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; ALPHA INTERFERON;

AGED; ARTICLE; ASTHENIA; AXILLARY LYMPH NODE; B LYMPHOCYTE; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FEVER; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HEMATOPOIETIC SYSTEM; HISTOPATHOLOGY; HUMAN; HYPERGAMMAGLOBULINEMIA; HYPERPLASIA; LIVER TOXICITY; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHADENOPATHY; MACROPHAGE; MAINTENANCE THERAPY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRURITUS; SPLENOMEGALY; T LYMPHOCYTE; URTICARIA; WHOLE BODY RADIATION; CANCER STAGING; CHEMICALLY INDUCED DISORDER; INFUSION PUMP; LYMPHATIC SYSTEM DISEASE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOGRAPHY; SENTINEL LYMPH NODE BIOPSY; TREATMENT WITHDRAWAL;

AGED; COMBINED MODALITY THERAPY; FLUORODEOXYGLUCOSE F18; HUMANS; INFUSION PUMPS; INTERFERON-ALPHA; LYMPHATIC DISEASES; MALE; MELANOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SENTINEL LYMPH NODE BIOPSY; SPLENOMEGALY; WITHHOLDING TREATMENT;

EID: 63849258986     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181824d79     Document Type: Article

References (15)

1. Verma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006;106:1431-1442.
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
3. Kirkwood JM, Strawderman MH, Ernstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
4. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/ S9512/C509801. J Clin Oncol. 2001;19:2370-2380.
5. Eggermont AM, Suciu S, MacKie R, et al. EORTC Melanoma Group: post-surgery adjuvant therapy with intermediate doses of interferon alpha 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomized controlled trial. Lancet. 2005;366:1189-1196.
6. Kirkwood JM, Manola J, Ibrahim J, et al. Eastern Cooperative Oncology Group: a pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677.
7. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b. therapy. J Clin Oncol. 2002;20:3703-3718.
8. Chiarion-Sileni V, Del Bianco P, De Salvo GL, et al. Italian Melanoma Intergroup (IMI): quality of life evaluation in a randomized trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer. 2003;39:1577-1585.
9. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006;24:3164-3171.
10. Cone LA, Brochert A, Schulz K, et al. PET positive generalized lymphadenopathy and splenomegaly following interferon-alfa- 2b adjuvant therapy for melanoma. Clin Nucl Med. 2007;32: 793-796.
11. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32: 35-46.
12. Kazama T, Swanston N, Podoloff DA, et al. Effect of colonystimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl MedMol Imaging. 2005;32: 1406-1411.
13. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using ''quantitative'' parameters of FDG PET images. Clin Nucl Med. 1996;21:941.
14. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-718.
15. Ito N, Eto M, Nakamura E, et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol. 2007;25:2785-2791.